USANA Health Sciences Stock Price, News & Analysis (NYSE:USNA)

$68.83
-0.56 (-0.81 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$67.21
Now: $68.83
$69.59
50-Day Range
$64.29
MA: $68.34
$74.07
52-Week Range
$58.30
Now: $68.83
$125.61
Volume363,202 shs
Average Volume144,569 shs
Market Capitalization$1.53 billion
P/E Ratio13.34
Dividend YieldN/A
Beta0.39
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. Read More…

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryPersonal Products
SectorMedical
CUSIP90328M10
Phone801-954-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$5.9593 per share
Book Value$16.31 per share

Profitability

Net Income$126.22 million

Miscellaneous

Employees1,911
Market Cap$1.53 billion
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.


USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its board has authorized a share buyback plan on Tuesday, October 23rd 2018, which authorizes the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 5.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) released its quarterly earnings data on Tuesday, July, 23rd. The company reported $0.91 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.93 by $0.02. The company had revenue of $256 million for the quarter, compared to analyst estimates of $254.66 million. USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. USANA Health Sciences's revenue was down 15.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.36 EPS. View USANA Health Sciences' Earnings History.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for USANA Health Sciences.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY19 earnings guidance on Tuesday, July, 23rd. The company provided EPS guidance of $3.70-4.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.89. The company issued revenue guidance of $1.02-1.06 billion, compared to the consensus revenue estimate of $1.06 billion.

What price target have analysts set for USNA?

4 equities research analysts have issued 1-year target prices for USANA Health Sciences' stock. Their predictions range from $65.00 to $75.00. On average, they anticipate USANA Health Sciences' share price to reach $70.00 in the next year. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

What is the consensus analysts' recommendation for USANA Health Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for USANA Health Sciences.

Has USANA Health Sciences been receiving favorable news coverage?

News headlines about USNA stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. USANA Health Sciences earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for USANA Health Sciences.

Are investors shorting USANA Health Sciences?

USANA Health Sciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,563,200 shares, an increase of 14.9% from the July 31st total of 1,360,900 shares. Based on an average daily trading volume, of 361,600 shares, the short-interest ratio is currently 4.3 days. Currently, 12.2% of the shares of the stock are short sold. View USANA Health Sciences' Current Options Chain.

Who are some of USANA Health Sciences' key competitors?

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include Tableau Software (DATA), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Allergan (AGN), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR) and Vertex Pharmaceuticals (VRTX).

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the folowing people:
  • Dr. Myron W. Wentz, Founder & Chairman (Age 78)
  • Mr. Kevin G. Guest, CEO & Director (Age 56)
  • Mr. Jim Brown, Pres & COO (Age 50)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 49)
  • Mr. Walter Noot, Chief Information Officer (Age 53)

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.34%), Renaissance Technologies LLC (8.03%), Vanguard Group Inc. (6.45%), Acadian Asset Management LLC (3.49%), Morgan Stanley (1.34%) and D. E. Shaw & Co. Inc. (1.22%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

Which institutional investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Prudential Financial Inc., JPMorgan Chase & Co., AQR Capital Management LLC, Bank of America Corp DE, Wells Fargo & Company MN and Vanguard Group Inc.. Company insiders that have sold USANA Health Sciences company stock in the last year include Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert Auciaux and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

Which institutional investors are buying USANA Health Sciences stock?

USNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Schroder Investment Management Group, Wasatch Advisors Inc., Clark Estates Inc. NY, Invesco Ltd., D. E. Shaw & Co. Inc. and Boston Partners. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull and Myron W Wentz. View Insider Buying and Selling for USANA Health Sciences.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $68.83.

How big of a company is USANA Health Sciences?

USANA Health Sciences has a market capitalization of $1.53 billion and generates $1.19 billion in revenue each year. The company earns $126.22 million in net income (profit) each year or $5.16 on an earnings per share basis. USANA Health Sciences employs 1,911 workers across the globe.View Additional Information About USANA Health Sciences.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is http://www.usana.com/.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]


MarketBeat Community Rating for USANA Health Sciences (NYSE USNA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  383 (Vote Underperform)
Total Votes:  673
MarketBeat's community ratings are surveys of what our community members think about USANA Health Sciences and other stocks. Vote "Outperform" if you believe USNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel